Articles On Dimerix (ASX:DXB)

The FDA has told Telix to do more work on its imaging agent for rare brain cancers But the agency tells Dimerix it can use a surrogate endpoint for its kidney disease drug candidate Emvision opens a second US site to test its stroke detect...

FDA confirms a proteinuria-based endpoint could be basis for full marketing approval of DMX-200 in the US FDA proposal aligns with existing DMX-200 preclinical and clinical efficacy results No additional changes anticipated to the ACTION3...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

Highlights Dimerix Limited has quoted new fully paid ordinary securities on the ASX under code DXB. The company focuses on developing treatments for kidney and respiratory conditions. The listing aims to expand financial cap...

ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir  HealthIn...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on April 2 Event to highlight some of ASX’s leading up-and-coming health and life sciences companies EMVision, Microba Life Sciences, Orthocell, Lumos Diagnosti...

Highlights: ASX market fluctuations bring varied performances across sectors. Health Care and Telecommunications display resilience, while Utilities and Real Estate show a different trajectory. Several ASX-listed companies p...

 Proteomics launches its diabetic kidney disease assay in Australia Trivarx lines up a sleep-related depression study with US Veterans Affairs The vibes from Trumpland are not great for research-stage biotechs   It’s World Kidney Day, whe...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...

ASX health stocks fell 0.43% over the past week, while the broader market 2.51% ProMedicus has signed a seven-year, $40 million deal with leading US radiology provider LucidHealth Opthea falls following release of half-year results as it a...

Healthcare leaders stress need for more women in leadership in ASX biotech sector ImpediMed’s female CEO and chair understand challenges for women in sector Dimerix CEO and MD Dr Nina Webster believes workplace flexibility helps women bala...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Dimerix receives upfront payment of ¥300 million (~A$3.2 million) from FUSO Pharmaceutical Industries under licensing deal Company recently inked licensing deal with Japanese company for phase III asset in kidney disease DMX-200 Dimerix el...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January. Under that deal, FUSO and Dimerix teamed up to develop and commercialise D...

Polynovo and Avita Medical are victims of skittish market behaviour Cyclopharm breathes easier after a good start with US sales Control Bionics raises $2 million to rev up commercialisation   Investor reaction to PolyNovo’s (ASX:PNV) half...

Middle East healthcare sector undergoing rapid expansion presenting opportunities for ASX-listed companies ImpediMed has a distributor in Qatar for its SOZO bioimpedance spectroscopy (BIS) device for early detection and prevention of lymph...

Highlights Rapid sector growth offers new prospects for ASX-listed healthcare firms Key players (IPD,DXB,IMR) are enhancing regional presence Rising demand driven by innovation and demographic trends fuels market expansion The healthc...

ASX healthcare leaders are often involved in multiple companies or organisations  Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia Dimerix CEO and MD Dr Nina Webster has two other key positions...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

The ASX200 closed up 1.38% at 8,327 points. Unemployment ticked up to 4%, in line with consensus expectations. The strong jobs data has increased the threshold on what the RBA will need to see in the December quarter inflation numbers fo...

ASX jumps on strong banks and jobs report Zip and Tabcorp surge as markets rally Oil prices soar amid supply risks and cold weather   The ASX flexed its muscles today, up 1.38% on the back of strong bank gains and a bit of global risk-on...

Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3 clinical trial in a major next step for the research. The trial will investigate the...

Pro Medicus signs $33m deal with University of Kentucky Memphasys’ RoXsta system advances antioxidant profiling potential Acrux launches 90-gram Dapsone Gel in US   These are today’s healthcare announcements from the ASX, with major progr...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, inc...

Highlights Dimerix (ASX:DXB) successfully enrolls its first pediatric patient in the ACTION3 trial targeting FSGS. The ACTION3 trial spans 19 sites across multiple countries, with a focus on pediatric patients aged 12 to 17. Successfu...

This week’s Bulls N’ Bears Runner of the Week is … Sparc Technologies. The company is developing new-age hydrogen technology using sunlight, while Argent Biopharma, Australian Mines and Dimerix also ran hard.

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

ASX 200 lifts on tech rally, miners struggle Barrick Gold threatens Mali shutdown over shipping restrictions Bitcoin bounces back after recent slump   The ASX 200 index crept up 0.34% on Tuesday, thanks to a rally in tech following the Na...

Opyl enters joint venture with X Firm to market its AI-powered TrialKey platform in Europe, Middle East, Africa and North America Dimerix enters exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-20...

The ASX200 has been up one fifth of a percent (0.2%) at 8,273 points in afternoon trade. Canada’s Prime Minister Justin Trudeau has resigned and the country’s main stock index fell on Monday; the Loonie notched a near three-week high. Bo...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Fraser Palamara tells all on Dimerix’s (ASX:DXB) new partner in Japan’s FUSO Pharmaceutical Industries to develop a drug candidate in fig...

Dimerix enters exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-200 in Japan to treat FSGS Fuso responsible for development costs, obtaining regulatory approval, sales and marketing in Japan Deal...

Biopharmaceutical company Dimerix Ltd (ASX:DXB) has partnered with Japanese company FUSO to progress the development and commercialisation of its drug DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease....

Dimerix Ltd (ASX: DXB) shares are catching the eye of investors on Tuesday. In morning trade, the ASX healthcare stock is up 31% to 46.5 cents. Why is this ASX healthcare stock rocketing? Investors have been fighting to get hold of the clin...

The ASX 200 index is expected to open as much as 0.36% higher today, adding 29.9 points in futures, which would mark the local bourse’s fourth green day in a row – a trend it just barely held on to yesterday at close. U.S. markets were c...

The second last day of the year on the Australian stock exchange looks red, with the shortened holiday trading week’s futures down just over 29 points – a 0.35% drop – as the Aussie bourse grinds to a sluggish end to the 2025 season. The...

Highlights Market Performance: The ASX dipped 0.35% in early trading as global market pressures and profit-taking weighed on sentiment. Sector Impacts: Key players in tech and retail, including Microsoft and Amazon, showed declines,...

Highlights - ASX faced a modest dip amid global caution and ex-dividend activity.  - BrainChip Holdings (BRN) soared despite no clear catalyst for its rise.  - Prominent small-cap stocks showcased diverse developments and partnerships....

Morgans sees opportunities among several ASX healthcare stocks in 2025 Broker looking at stocks with near-term catalysts or sold down with good entry opportunities Morgans’ Christmas stocking has mix of up-and-comers alongside mature names...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

Syntara aims for FDA ‘breakthrough’ therapy status for its myelofibrosis drug candidate FAK! More promising results from Amplia’s pancreatic cancer trial Oh, you shouldn’t have! Broker Morgans’ Christmas biotech hamper   Armed with encour...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX dips as energy stocks lead losses Global tensions weigh on markets, gold stocks rise China holds rates steady, Nvidia’s earnings later tonight   The ASX slipped from Tuesday’s high, closing lower by 0.57% on Wednesday.  Global worries...

ASX rises, but MinRes drops over transparency issues Fed boss Powell’s cautious rate cut stance cools market optimism NoviqTech shares surge after securing blockchain funding   The ASX rose by 0.74% on Friday, with 10 out of 11 sectors fi...

Several ASX healthcare companies have upcoming catalysts, which can be a focal point for healthcare investors Dimerix forecasts the second interim analysis of its ACTION 3 global phase III trial of DMX-200 to treat FSGS in around mid-CY25...